Alector Key Executives
This section highlights Alector's key executives, including their titles and compensation details.
Find Contacts at Alector
(Showing 0 of )
Alector Earnings
This section highlights Alector's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-08 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-27 | $-0.80 | $-0.49 |
| Read Transcript | Q2 | 2023 | 2023-08-04 | N/A | N/A |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
$0.89
Stock Price
$88.29M
Market Cap
238
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Alector, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $100.56M | $97.06M | $133.62M | $207.09M | $21.10M |
| Cost of Revenue | $- | $192.12M | $8.47M | $189.41M | $156.87M |
| Gross Profit | $100.56M | $-95.05M | $125.14M | $17.68M | $-135.77M |
| Gross Profit Ratio | 100.00% | -97.93% | 93.66% | 8.54% | -643.53% |
| Research and Development Expenses | $185.94M | $192.12M | $210.42M | $189.41M | $156.87M |
| General and Administrative Expenses | $59.62M | $56.69M | $61.03M | $55.04M | $59.40M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $59.62M | $56.69M | $61.03M | $55.04M | $59.40M |
| Other Expenses | $- | $- | $7.78M | $1.03M | $4.95M |
| Operating Expenses | $245.56M | $248.80M | $271.45M | $244.44M | $216.27M |
| Cost and Expenses | $245.56M | $248.80M | $271.45M | $244.44M | $216.27M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $8.85M | $8.47M | $8.31M | $7.26M |
| EBITDA | $-145.00M | $-142.89M | $-129.36M | $-29.05M | $-187.91M |
| EBITDA Ratio | -144.19% | -147.22% | -96.82% | -14.03% | -890.65% |
| Operating Income | $-145.00M | $-151.74M | $-137.83M | $-37.36M | $-195.17M |
| Operating Income Ratio | -144.19% | -156.33% | -103.16% | -18.04% | -925.08% |
| Total Other Income Expenses Net | $26.08M | $26.56M | $7.78M | $1.03M | $4.95M |
| Income Before Tax | $-118.92M | $-125.18M | $-130.06M | $-36.33M | $-190.23M |
| Income Before Tax Ratio | -118.26% | -128.97% | -97.33% | -17.54% | -901.64% |
| Income Tax Expense | $128.00K | $5.21M | $3.25M | $-8.31M | $-7.26M |
| Net Income | $-119.05M | $-130.39M | $-133.31M | $-28.01M | $-182.96M |
| Net Income Ratio | -118.39% | -134.34% | -99.77% | -13.53% | -867.21% |
| EPS | $-1.23 | $-1.56 | $-1.62 | $-0.35 | $-2.35 |
| EPS Diluted | $-1.23 | $-1.56 | $-1.62 | $-0.35 | $-2.35 |
| Weighted Average Shares Outstanding | 96.59M | 83.73M | 82.47M | 80.42M | 77.76M |
| Weighted Average Shares Outstanding Diluted | 96.59M | 83.73M | 82.47M | 80.42M | 77.76M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.24M | $15.34M | $15.08M | $15.89M | $15.19M | $9.11M | $56.21M | $16.55M | $14.44M | $14.85M | $79.85M | $24.47M | $13.99M | $182.41M | $6.57M | $4.11M | $4.85M | $5.90M | $3.17M | $7.17M |
| Cost of Revenue | $- | $- | $2.28M | $2.29M | $6.59M | $2.26M | $2.23M | $2.10M | $2.11M | $2.04M | $54.53M | $53.04M | $52.79M | $43.07M | $47.82M | $45.73M | $44.38M | $43.82M | $34.06M | $34.60M |
| Gross Profit | $54.24M | $15.34M | $12.80M | $13.60M | $8.60M | $6.85M | $53.98M | $14.45M | $12.33M | $12.81M | $25.32M | $-28.57M | $-38.80M | $139.35M | $-41.25M | $-41.62M | $-39.53M | $-37.91M | $-30.89M | $-27.43M |
| Gross Profit Ratio | 100.00% | 100.00% | 84.88% | 85.58% | 56.62% | 75.22% | 96.03% | 87.30% | 85.37% | 86.24% | 31.71% | -116.73% | -277.23% | 76.39% | -628.05% | -1012.73% | -814.55% | -642.19% | -974.51% | -382.57% |
| Research and Development Expenses | $46.46M | $48.00M | $44.03M | $45.17M | $47.72M | $46.33M | $46.18M | $51.89M | $54.49M | $48.35M | $54.53M | $53.04M | $52.79M | $43.07M | $47.82M | $45.73M | $44.38M | $43.82M | $34.06M | $34.60M |
| General and Administrative Expenses | $15.03M | $15.78M | $14.38M | $14.43M | $14.92M | $13.36M | $13.63M | $14.78M | $15.38M | $14.25M | $15.84M | $15.55M | $16.93M | $13.02M | $14.07M | $11.01M | $13.23M | $15.83M | $15.70M | $14.64M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $15.03M | $15.78M | $14.38M | $14.43M | $14.92M | $13.36M | $13.63M | $14.78M | $15.38M | $14.25M | $15.84M | $15.55M | $16.93M | $13.02M | $14.07M | $11.01M | $13.23M | $15.83M | $15.70M | $14.64M |
| Other Expenses | $- | $- | $7.00M | $7.64M | $7.68M | $7.36M | $6.36M | $5.16M | $3.73M | $2.33M | $1.45M | $264.00K | $121.00K | $268.00K | $178.00K | $464.00K | $579.00K | $1.04M | $1.26M | $2.06M |
| Operating Expenses | $61.49M | $63.78M | $58.41M | $59.60M | $62.64M | $59.69M | $59.80M | $66.66M | $69.88M | $62.60M | $70.38M | $68.60M | $69.72M | $56.08M | $61.89M | $56.74M | $57.61M | $59.65M | $49.76M | $49.25M |
| Cost and Expenses | $61.49M | $63.78M | $60.69M | $59.60M | $62.64M | $59.69M | $59.80M | $66.66M | $69.88M | $62.60M | $70.38M | $68.60M | $69.72M | $56.08M | $61.89M | $56.74M | $57.61M | $59.65M | $49.76M | $49.25M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $5.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $2.08M | $2.19M | $2.28M | $2.29M | $2.26M | $2.26M | $2.23M | $2.10M | $2.11M | $2.04M | $2.06M | $2.26M | $2.15M | $2.10M | $2.07M | $2.00M | $1.96M | $1.79M | $1.77M | $1.74M |
| EBITDA | $-5.17M | $-46.24M | $-44.20M | $-42.27M | $-46.02M | $-49.12M | $-2.12M | $-48.76M | $-54.04M | $-45.70M | $11.53M | $-41.60M | $-53.46M | $128.43M | $-53.26M | $-50.63M | $-50.22M | $-52.28M | $-45.13M | $-40.63M |
| EBITDA Ratio | -9.53% | -301.41% | -293.06% | -265.93% | -302.94% | -539.24% | -3.78% | -294.61% | -374.27% | -307.74% | 14.44% | -169.98% | -382.04% | 70.41% | -810.89% | -1231.95% | -1034.72% | -885.59% | -1423.72% | -566.62% |
| Operating Income | $-7.25M | $-48.43M | $-45.61M | $-43.71M | $-47.45M | $-50.58M | $-3.59M | $-50.12M | $-55.44M | $-47.75M | $9.47M | $-44.12M | $-55.73M | $126.33M | $-55.33M | $-52.63M | $-52.76M | $-53.75M | $-46.59M | $-42.08M |
| Operating Income Ratio | -13.36% | -315.70% | -302.37% | -275.01% | -312.40% | -555.31% | -6.38% | -302.83% | -383.92% | -321.49% | 11.87% | -180.29% | -398.23% | 69.25% | -842.34% | -1280.66% | -1087.12% | -910.38% | -1469.68% | -586.78% |
| Total Other Income Expenses Net | $5.22M | $6.21M | $7.00M | $7.64M | $7.68M | $7.36M | $6.36M | $5.16M | $3.73M | $2.33M | $1.45M | $264.00K | $121.00K | $268.00K | $178.00K | $464.00K | $579.00K | $1.04M | $1.26M | $2.06M |
| Income Before Tax | $-2.03M | $-42.22M | $-38.60M | $-36.07M | $-39.77M | $-43.22M | $2.77M | $-44.96M | $-51.71M | $-45.41M | $10.93M | $-43.86M | $-55.61M | $126.60M | $-55.15M | $-52.17M | $-52.18M | $-52.70M | $-45.33M | $-40.02M |
| Income Before Tax Ratio | -3.74% | -275.19% | -255.94% | -226.97% | -261.80% | -474.51% | 4.92% | -271.65% | -358.08% | -305.78% | 13.68% | -179.21% | -397.37% | 69.40% | -839.63% | -1269.37% | -1075.19% | -892.68% | -1429.84% | -558.07% |
| Income Tax Expense | $48.00K | $- | $73.00K | $7.00K | $1.67M | $1.25M | $1.39M | $901.00K | $721.00K | $733.00K | $1.04M | $758.00K | $-2.15M | $- | $1 | $1 | $-1.96M | $- | $- | $- |
| Net Income | $-2.07M | $-42.22M | $-38.68M | $-36.08M | $-41.43M | $-44.48M | $1.38M | $-45.86M | $-52.43M | $-46.15M | $9.88M | $-44.62M | $-55.61M | $126.60M | $-55.15M | $-52.17M | $-52.18M | $-52.70M | $-45.33M | $-40.02M |
| Net Income Ratio | -3.82% | -275.19% | -256.42% | -227.01% | -272.77% | -488.25% | 2.45% | -277.10% | -363.07% | -310.72% | 12.38% | -182.30% | -397.37% | 69.40% | -839.63% | -1269.37% | -1075.19% | -892.68% | -1429.84% | -558.07% |
| EPS | $-0.02 | $-0.44 | $-0.40 | $-0.38 | $-0.49 | $-0.53 | $0.02 | $-0.55 | $-0.63 | $-0.56 | $0.12 | $-0.54 | $-0.68 | $1.56 | $-0.69 | $-0.66 | $-0.67 | $-0.67 | $-0.58 | $-0.53 |
| EPS Diluted | $-0.02 | $-0.44 | $-0.40 | $-0.38 | $-0.49 | $-0.53 | $0.02 | $-0.55 | $-0.63 | $-0.56 | $0.12 | $-0.54 | $-0.68 | $1.49 | $-0.69 | $-0.66 | $-0.66 | $-0.67 | $-0.58 | $-0.53 |
| Weighted Average Shares Outstanding | 96.63M | 96.67M | 96.67M | 93.81M | 84.38M | 83.93M | 83.50M | 83.10M | 82.76M | 82.60M | 82.39M | 82.10M | 81.51M | 80.96M | 79.79M | 79.39M | 78.42M | 78.66M | 78.42M | 74.82M |
| Weighted Average Shares Outstanding Diluted | 96.63M | 96.67M | 96.67M | 93.81M | 84.38M | 83.93M | 83.57M | 83.10M | 82.76M | 82.60M | 82.59M | 82.10M | 81.51M | 85.23M | 79.79M | 79.39M | 79.00M | 78.77M | 78.42M | 74.82M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $33.02M | $74.56M | $154.32M | $329.15M | $49.97M |
| Short Term Investments | $380.38M | $474.31M | $558.53M | $406.10M | $363.34M |
| Cash and Short Term Investments | $413.40M | $548.86M | $712.85M | $735.25M | $413.31M |
| Net Receivables | $- | $- | $2.59M | $7.39M | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $11.42M | $16.95M | $11.00M | $7.07M | $16.41M |
| Total Current Assets | $424.82M | $565.81M | $726.43M | $749.71M | $421.51M |
| Property Plant Equipment Net | $37.10M | $47.06M | $53.33M | $57.90M | $62.65M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.47M | $1.47M | $1.47M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.39M | $8.96M | $6.41M | $5.57M | $2.62M |
| Total Non-Current Assets | $43.49M | $56.02M | $61.21M | $64.94M | $66.74M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $468.30M | $621.83M | $787.65M | $814.66M | $488.25M |
| Account Payables | $2.21M | $3.77M | $4.19M | $4.75M | $3.00M |
| Short Term Debt | $8.75M | $8.46M | $8.06M | $15.59M | $15.02M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $23.66M | $82.97M | $48.23M | $90.80M | $23.89M |
| Other Current Liabilities | $90.43M | $82.74M | $33.33M | $28.41M | $26.17M |
| Total Current Liabilities | $125.06M | $177.95M | $45.58M | $48.22M | $44.20M |
| Long Term Debt | $33.77M | $30.46M | $35.27M | $39.81M | $43.74M |
| Deferred Revenue Non-Current | $- | $210.84M | $491.60M | $425.22M | $132.30M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $534.00K | $- |
| Other Non-Current Liabilities | $182.68M | $68.42M | $759.00K | $158.00K | $472.00K |
| Total Non-Current Liabilities | $216.44M | $309.72M | $527.63M | $465.72M | $176.52M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $341.50M | $487.67M | $573.21M | $513.93M | $220.72M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $8.00K | $8.00K | $8.00K | $8.00K |
| Retained Earnings | $-829.13M | $-710.08M | $-579.69M | $-446.38M | $-410.05M |
| Accumulated Other Comprehensive Income Loss | $261.00K | $184.00K | $-4.58M | $-943.00K | $614.00K |
| Other Total Stockholders Equity | $955.66M | $844.04M | $798.70M | $748.04M | $676.96M |
| Total Stockholders Equity | $126.80M | $134.16M | $214.44M | $300.72M | $267.53M |
| Total Equity | $126.80M | $134.16M | $214.44M | $300.72M | $267.53M |
| Total Liabilities and Stockholders Equity | $468.30M | $621.83M | $787.65M | $814.66M | $488.25M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $468.30M | $621.83M | $787.65M | $814.66M | $488.25M |
| Total Investments | $380.38M | $474.31M | $558.53M | $406.10M | $363.34M |
| Total Debt | $42.52M | $38.92M | $43.33M | $47.60M | $51.26M |
| Net Debt | $9.50M | $-35.64M | $-111.00M | $-281.55M | $1.29M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $33.02M | $37.16M | $47.55M | $72.55M | $74.56M | $101.96M | $131.54M | $195.56M | $154.32M | $184.23M | $172.26M | $454.62M | $329.15M | $516.53M | $125.71M | $110.70M | $49.97M | $84.98M | $92.50M | $160.92M |
| Short Term Investments | $380.38M | $420.04M | $455.79M | $489.53M | $474.31M | $486.90M | $498.51M | $473.77M | $558.53M | $574.08M | $636.59M | $413.95M | $406.10M | $261.32M | $193.86M | $252.04M | $363.34M | $376.74M | $411.14M | $387.62M |
| Cash and Short Term Investments | $413.40M | $457.20M | $503.33M | $562.08M | $548.86M | $588.86M | $630.05M | $669.33M | $712.85M | $758.31M | $808.86M | $868.57M | $735.25M | $777.85M | $319.57M | $362.74M | $413.31M | $461.71M | $503.64M | $548.53M |
| Net Receivables | $- | $- | $- | $- | $- | $10.46M | $7.83M | $4.70M | $2.59M | $6.49M | $8.82M | $12.82M | $7.39M | $1.58M | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $11.42M | $12.16M | $16.37M | $19.31M | $16.95M | $13.82M | $10.12M | $11.97M | $11.00M | $10.17M | $9.35M | $9.54M | $7.07M | $8.59M | $19.52M | $23.99M | $16.41M | $15.40M | $11.50M | $13.84M |
| Total Current Assets | $424.82M | $469.36M | $519.70M | $581.39M | $565.81M | $613.15M | $647.99M | $686.00M | $726.43M | $774.96M | $827.02M | $890.93M | $749.71M | $788.02M | $329.33M | $374.74M | $421.51M | $470.01M | $510.09M | $556.20M |
| Property Plant Equipment Net | $37.10M | $39.02M | $43.37M | $45.16M | $47.06M | $49.15M | $50.59M | $52.06M | $53.33M | $54.82M | $55.26M | $56.13M | $57.90M | $59.02M | $60.32M | $61.56M | $62.65M | $57.89M | $59.38M | $60.85M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.47M | $1.47M | $1.47M | $1.47M | $1.47M | $1.47M | $1.47M | $1.47M | $1.47M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.39M | $7.63M | $6.12M | $7.40M | $7.42M | $8.55M | $8.61M | $8.80M | $6.41M | $5.78M | $5.92M | $5.93M | $5.57M | $5.72M | $5.99M | $2.59M | $4.09M | $3.69M | $2.56M | $1.88M |
| Total Non-Current Assets | $43.49M | $46.66M | $51.03M | $54.10M | $56.02M | $59.25M | $60.74M | $62.34M | $61.21M | $62.08M | $62.65M | $63.53M | $64.94M | $66.21M | $67.78M | $65.63M | $66.74M | $61.58M | $61.94M | $62.72M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $468.30M | $516.02M | $570.73M | $635.49M | $621.83M | $672.39M | $708.74M | $748.34M | $787.65M | $837.04M | $889.67M | $954.46M | $814.66M | $854.23M | $397.11M | $440.36M | $488.25M | $531.59M | $572.03M | $618.93M |
| Account Payables | $2.21M | $5.02M | $4.38M | $4.59M | $3.77M | $4.68M | $4.67M | $3.13M | $4.19M | $4.55M | $4.65M | $6.75M | $4.75M | $2.34M | $11.94M | $5.31M | $3.00M | $1.37M | $4.76M | $4.04M |
| Short Term Debt | $8.75M | $15.45M | $17.21M | $8.54M | $16.92M | $16.78M | $16.40M | $16.26M | $8.06M | $15.98M | $15.84M | $15.71M | $7.79M | $15.57M | $15.52M | $15.40M | $7.51M | $13.47M | $13.36M | $13.25M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $23.66M | $55.43M | $63.96M | $73.35M | $82.97M | $80.56M | $68.55M | $61.77M | $48.23M | $119.68M | $106.99M | $95.61M | $90.80M | $94.68M | $25.42M | $22.70M | $23.89M | $26.60M | $32.74M | $32.09M |
| Other Current Liabilities | $90.43M | $73.40M | $62.13M | $78.44M | $74.27M | $53.38M | $42.66M | $18.14M | $33.33M | $20.68M | $21.93M | $24.80M | $36.21M | $20.22M | $21.51M | $20.66M | $33.69M | $29.65M | $8.32M | $22.40M |
| Total Current Liabilities | $125.06M | $142.53M | $147.68M | $164.92M | $177.95M | $155.40M | $132.27M | $99.30M | $45.58M | $160.89M | $149.41M | $142.88M | $48.22M | $132.81M | $74.39M | $64.06M | $44.20M | $71.09M | $65.86M | $71.78M |
| Long Term Debt | $33.77M | $25.96M | $27.51M | $29.02M | $30.46M | $31.84M | $32.74M | $34.05M | $35.27M | $36.45M | $37.62M | $38.75M | $39.81M | $40.83M | $41.84M | $42.82M | $43.74M | $39.26M | $40.03M | $40.78M |
| Deferred Revenue Non-Current | $172.17M | $- | $199.58M | $204.57M | $210.84M | $229.85M | $245.34M | $431.08M | $491.60M | $386.36M | $413.90M | $505.13M | $425.22M | $344.53M | $96.21M | $105.49M | $132.30M | $110.56M | $110.32M | $114.14M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $56.70M | $67.05M | $91.85M | $101.17M | $- | $- | $- | $- | $- | $534.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $10.51M | $228.61M | $45.39M | $1.37M | $68.42M | $92.75M | $102.07M | $898.00K | $759.00K | $233.00K | $233.00K | $158.00K | $158.00K | $158.00K | $158.00K | $158.00K | $472.00K | $493.00K | $493.00K | $493.00K |
| Total Non-Current Liabilities | $216.44M | $254.56M | $272.48M | $291.67M | $309.72M | $354.44M | $380.16M | $466.03M | $527.63M | $423.05M | $451.75M | $544.04M | $465.72M | $385.52M | $138.21M | $148.47M | $176.52M | $150.31M | $150.84M | $155.42M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $341.50M | $397.09M | $420.16M | $456.59M | $487.67M | $509.84M | $512.43M | $565.33M | $573.21M | $583.93M | $601.16M | $686.92M | $513.93M | $518.34M | $212.60M | $212.53M | $220.72M | $221.40M | $216.70M | $227.19M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $9.00K | $9.00K | $9.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K | $8.00K |
| Retained Earnings | $-829.13M | $-827.05M | $-784.83M | $-746.16M | $-710.08M | $-668.64M | $-624.17M | $-625.54M | $-579.69M | $-527.26M | $-481.11M | $-490.99M | $-446.38M | $-390.77M | $-517.37M | $-462.22M | $-410.05M | $-357.87M | $-305.17M | $-259.84M |
| Accumulated Other Comprehensive Income Loss | $261.00K | $931.00K | $-620.00K | $-403.00K | $184.00K | $-721.00K | $-1.39M | $-2.20M | $-4.58M | $-6.74M | $-6.22M | $-3.94M | $-943.00K | $-41.00K | $203.00K | $410.00K | $614.00K | $1.09M | $1.85M | $2.78M |
| Other Total Stockholders Equity | $955.66M | $945.05M | $936.01M | $925.46M | $844.04M | $831.91M | $821.85M | $810.75M | $798.70M | $787.10M | $775.84M | $762.46M | $748.04M | $726.69M | $701.67M | $689.63M | $676.96M | $666.96M | $658.64M | $648.78M |
| Total Stockholders Equity | $126.80M | $118.93M | $150.57M | $178.91M | $134.16M | $162.56M | $196.31M | $183.01M | $214.44M | $253.10M | $288.52M | $267.54M | $300.72M | $335.89M | $184.51M | $227.83M | $267.53M | $310.19M | $355.33M | $391.73M |
| Total Equity | $126.80M | $118.93M | $150.57M | $178.91M | $134.16M | $162.56M | $196.31M | $183.01M | $214.44M | $253.10M | $288.52M | $267.54M | $300.72M | $335.89M | $184.51M | $227.83M | $267.53M | $310.19M | $355.33M | $391.73M |
| Total Liabilities and Stockholders Equity | $468.30M | $516.02M | $570.73M | $635.49M | $621.83M | $672.39M | $708.74M | $748.34M | $787.65M | $837.04M | $889.67M | $954.46M | $814.66M | $854.23M | $397.11M | $440.36M | $488.25M | $531.59M | $572.03M | $618.93M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $468.30M | $516.02M | $570.73M | $635.49M | $621.83M | $672.39M | $708.74M | $748.34M | $787.65M | $837.04M | $889.67M | $954.46M | $814.66M | $854.23M | $397.11M | $440.36M | $488.25M | $531.59M | $572.03M | $618.93M |
| Total Investments | $380.38M | $420.04M | $457.33M | $489.53M | $474.31M | $486.90M | $498.51M | $473.77M | $558.53M | $574.08M | $636.59M | $413.95M | $406.10M | $261.32M | $193.86M | $252.04M | $363.34M | $376.74M | $411.14M | $387.62M |
| Total Debt | $42.52M | $34.64M | $36.11M | $37.56M | $38.92M | $40.23M | $40.94M | $42.18M | $43.33M | $44.45M | $45.54M | $46.61M | $47.60M | $48.62M | $49.60M | $50.52M | $51.26M | $45.99M | $46.71M | $47.41M |
| Net Debt | $9.50M | $-2.52M | $-11.43M | $-34.99M | $-35.64M | $-61.73M | $-90.60M | $-153.38M | $-111.00M | $-139.79M | $-126.73M | $-408.01M | $-281.55M | $-467.91M | $-76.11M | $-60.18M | $1.29M | $-38.99M | $-45.79M | $-113.51M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-119.05M | $-130.39M | $-133.31M | $-36.33M | $-190.23M |
| Depreciation and Amortization | $-8.97M | $8.85M | $8.47M | $8.31M | $7.26M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $39.46M | $42.80M | $46.15M | $40.78M | $30.52M |
| Change in Working Capital | $-146.99M | $-90.15M | $59.53M | $283.68M | $-15.22M |
| Accounts Receivables | $- | $2.59M | $4.80M | $-7.39M | $- |
| Inventory | $- | $- | $-4.80M | $7.39M | $- |
| Accounts Payables | $-1.44M | $-377.00K | $-572.00K | $1.92M | $2.41M |
| Other Working Capital | $-145.54M | $-92.36M | $60.10M | $281.76M | $-17.63M |
| Other Non Cash Items | $5.64M | $-15.27M | $-1.16M | $2.10M | $929.00K |
| Net Cash Provided by Operating Activities | $-229.91M | $-184.16M | $-20.33M | $298.55M | $-166.73M |
| Investments in Property Plant and Equipment | $-1.25M | $-2.38M | $-4.12M | $-3.25M | $-5.03M |
| Acquisitions Net | $- | $- | $159.01M | $49.66M | $100.02M |
| Purchases of Investments | $-467.74M | $-551.73M | $-556.90M | $-343.40M | $-506.81M |
| Sales Maturities of Investments | $576.13M | $656.03M | $402.00M | $296.99M | $406.79M |
| Other Investing Activities | $- | $- | $-159.01M | $-49.66M | $-100.02M |
| Net Cash Used for Investing Activities | $107.13M | $101.92M | $-159.01M | $-49.66M | $-105.05M |
| Debt Repayment | $9.39M | $- | $- | $- | $- |
| Common Stock Issued | $71.11M | $2.55M | $4.51M | $30.30M | $224.60M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.04M | $2.55M | $4.51M | $30.30M | $7.51M |
| Net Cash Used Provided by Financing Activities | $81.54M | $2.55M | $4.51M | $30.30M | $232.11M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-41.23M | $-79.69M | $-174.83M | $279.18M | $-39.67M |
| Cash at End of Period | $34.87M | $76.10M | $155.79M | $330.62M | $51.44M |
| Cash at Beginning of Period | $76.10M | $155.79M | $330.62M | $51.44M | $91.11M |
| Operating Cash Flow | $-229.91M | $-184.16M | $-20.33M | $298.55M | $-166.73M |
| Capital Expenditure | $-1.25M | $-2.38M | $-4.12M | $-3.25M | $-5.03M |
| Free Cash Flow | $-231.16M | $-186.54M | $-24.45M | $295.30M | $-171.77M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.07M | $-42.22M | $-38.68M | $-36.08M | $-41.43M | $-44.48M | $1.38M | $-45.86M | $-52.43M | $-46.15M | $9.88M | $-44.62M | $-55.61M | $126.60M | $-55.15M | $-52.17M | $-52.18M | $-52.70M | $-45.33M | $-40.02M |
| Depreciation and Amortization | $2.08M | $-12.21M | $2.28M | $2.29M | $2.26M | $2.26M | $2.23M | $2.10M | $2.11M | $2.04M | $2.06M | $2.26M | $2.15M | $2.10M | $2.07M | $2.00M | $1.96M | $1.79M | $1.77M | $1.74M |
| Deferred Income Tax | $- | $- | $- | $- | $-27.68M | $12.95M | $14.73M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $10.21M | $9.04M | $9.91M | $10.31M | $11.54M | $10.06M | $10.22M | $10.97M | $10.96M | $10.77M | $12.48M | $11.94M | $12.71M | $10.20M | $9.08M | $8.80M | $8.90M | $8.03M | $6.95M | $6.64M |
| Change in Working Capital | $-62.66M | $-4.03M | $-32.35M | $-33.29M | $-13.68M | $-9.79M | $-53.51M | $-13.17M | $-8.14M | $-15.27M | $-82.01M | $164.94M | $-9.02M | $305.72M | $-1.10M | $-11.92M | $-7.02M | $1.56M | $-9.32M | $-448.00K |
| Accounts Receivables | $- | $- | $- | $- | $7.88M | $-2.64M | $-3.13M | $-2.11M | $3.90M | $2.33M | $4.00M | $-5.43M | $-5.81M | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-7.88M | $2.64M | $3.13M | $2.11M | $-3.90M | $-2.33M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.77M | $690.00K | $-275.00K | $918.00K | $-1.01M | $4.00K | $1.55M | $-914.00K | $-189.00K | $147.00K | $-2.57M | $2.04M | $2.26M | $-9.49M | $6.56M | $2.59M | $1.32M | $-3.34M | $1.30M | $3.13M |
| Other Working Capital | $-59.89M | $-4.72M | $-32.08M | $-15.89M | $-12.66M | $-9.79M | $-55.06M | $-12.26M | $-7.95M | $-15.41M | $-79.85M | $162.90M | $-11.29M | $315.21M | $-7.65M | $-14.51M | $-8.34M | $4.91M | $-10.62M | $-3.58M |
| Other Non Cash Items | $-2.58M | $-1.31M | $10.79M | $9.39M | $22.92M | $-17.54M | $-18.05M | $-2.60M | $-1.43M | $-449.00K | $-82.28M | $570.00K | $513.00K | $434.00K | $558.00K | $594.00K | $671.00K | $499.00K | $-10.00K | $-231.00K |
| Net Cash Provided by Operating Activities | $-55.03M | $-50.73M | $-62.80M | $-61.35M | $-46.07M | $-46.54M | $-43.00M | $-48.55M | $-48.92M | $-49.05M | $-57.44M | $135.09M | $-49.27M | $445.05M | $-44.54M | $-52.69M | $-47.66M | $-40.82M | $-45.94M | $-32.31M |
| Investments in Property Plant and Equipment | $-173.00K | $-212.00K | $-337.00K | $-533.00K | $-233.00K | $94.00K | $-1.22M | $-1.02M | $-766.00K | $-1.92M | $-744.00K | $-692.00K | $-557.00K | $-915.00K | $-828.00K | $-947.00K | $-788.00K | $-381.00K | $-297.00K | $-3.57M |
| Acquisitions Net | $- | $- | $- | $- | $69.13M | $-16.87M | $20.60M | $-89.73M | $-19.15M | $-62.45M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-86.62M | $-83.35M | $-101.30M | $-196.47M | $-137.25M | $-145.97M | $-148.23M | $-120.27M | $-162.55M | $-73.06M | $-291.18M | $-30.11M | $-203.69M | $-134.63M | $-5.08M | $- | $-91.86M | $-107.56M | $-104.48M | $-202.91M |
| Sales Maturities of Investments | $128.20M | $123.91M | $138.79M | $185.23M | $155.56M | $162.84M | $127.63M | $210.00M | $181.70M | $135.50M | $66.10M | $18.70M | $57.49M | $66.50M | $62.50M | $110.50M | $104.20M | $140.96M | $80.03M | $81.60M |
| Other Investing Activities | $- | $- | $37.48M | $-11.23M | $-69.13M | $16.87M | $-20.60M | $89.73M | $19.15M | $62.45M | $-225.07M | $-11.41M | $-146.20M | $-68.14M | $57.42M | $110.50M | $12.34M | $33.39M | $-24.45M | $-121.31M |
| Net Cash Used for Investing Activities | $41.40M | $40.35M | $37.15M | $-11.77M | $18.07M | $16.96M | $-21.82M | $88.70M | $18.38M | $60.53M | $-225.82M | $-12.11M | $-146.75M | $-69.05M | $56.59M | $109.55M | $11.55M | $33.01M | $-24.74M | $-124.87M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $71.11M | $590.00K | $- | $881.00K | $1.08M | $636.00K | $489.00K | $906.00K | $2.48M | $8.64M | $14.82M | $2.96M | $3.87M | $-224.60M | $- | $-641.00K | $225.24M |
| Common Stock Repurchased | $- | $-12.23B | $12.23B | $- | $- | $- | $- | $- | $-865.00K | $- | $12.20B | $- | $- | $- | $9.44B | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $9.79M | $-71.75M | $644.00K | $- | $590.00K | $- | $881.00K | $1.08M | $636.00K | $489.00K | $906.00K | $2.48M | $8.64M | $14.82M | $2.96M | $3.87M | $1.10M | $286.00K | $2.27M | $3.22M |
| Net Cash Used Provided by Financing Activities | $9.79M | $- | $644.00K | $71.11M | $590.00K | $- | $881.00K | $1.08M | $636.00K | $489.00K | $906.00K | $2.48M | $8.64M | $14.82M | $2.96M | $3.87M | $1.10M | $286.00K | $2.27M | $228.46M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-83.26M | $1.27M | $81.99M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-3.84M | $-10.39M | $-25.01M | $-2.00M | $-27.41M | $-29.58M | $-63.94M | $41.23M | $-29.91M | $11.97M | $-282.36M | $125.47M | $-187.38M | $390.82M | $15.01M | $60.73M | $-35.01M | $-7.52M | $-68.42M | $71.28M |
| Cash at End of Period | $34.87M | $38.70M | $47.55M | $74.10M | $76.10M | $103.51M | $133.09M | $197.03M | $155.79M | $185.70M | $173.74M | $456.09M | $330.62M | $518.00M | $127.19M | $112.17M | $51.44M | $86.45M | $93.97M | $162.39M |
| Cash at Beginning of Period | $38.70M | $49.09M | $72.55M | $76.10M | $103.51M | $133.09M | $197.03M | $155.79M | $185.70M | $173.74M | $456.09M | $330.62M | $518.00M | $127.19M | $112.17M | $51.44M | $86.45M | $93.97M | $162.39M | $91.11M |
| Operating Cash Flow | $-55.03M | $-50.73M | $-62.80M | $-61.35M | $-46.07M | $-46.54M | $-43.00M | $-48.55M | $-48.92M | $-49.05M | $-57.44M | $135.09M | $-49.27M | $445.05M | $-44.54M | $-52.69M | $-47.66M | $-40.82M | $-45.94M | $-32.31M |
| Capital Expenditure | $-173.00K | $-212.00K | $-337.00K | $-533.00K | $-233.00K | $94.00K | $-1.22M | $-1.02M | $-766.00K | $-1.92M | $-744.00K | $-692.00K | $-557.00K | $-915.00K | $-828.00K | $-947.00K | $-788.00K | $-381.00K | $-297.00K | $-3.57M |
| Free Cash Flow | $-55.20M | $-50.95M | $-63.13M | $-61.88M | $-46.30M | $-46.45M | $-44.22M | $-49.57M | $-49.69M | $-50.97M | $-58.19M | $134.40M | $-49.82M | $444.14M | $-45.37M | $-53.64M | $-48.45M | $-41.20M | $-46.24M | $-35.88M |
Alector Dividends
Explore Alector's dividend history, including dividend yield, payout ratio, and historical payments.
Alector News
Read the latest news about Alector, including recent articles, headlines, and updates.
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m.
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024.
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ALEC.